Abstract:Immune checkpoint inhibitors (ICIs) such as PD-1 targeting antibodies nivolumab and pembrolizumab are FDA approved as therapies for many cancers. These ICIs inhibit PD-1 ligand binding, removing interference with T cell function, allowing T cell proliferation, and restoring the anti-tumor activity. Potential factors predicting checkpoint blockade success include PD-L1 expression, the presence of tumor infiltrating lymphocytes, microsatellite instability, and tumor mutational burden. ICIs are most effective clinically in combination therapies. Here, we devised a simple ICI gene therapy as a possible alternative to traditional and expensive monoclonal antibodies. We designed plasmids encoding the mouse sequences homologous to the nivolumab and pembrolizumab binding regions, which overlap the PD-1 ligand binding site. We hypothesized that, when produced intratumorally, each PD-1 peptide should bind PD-L1 and block T cell binding. Since B16F10 mouse melanoma cells and tumors express PD-L1, we tested this theory in this model. We directly demonstrated peptide-PD-L1 binding histologically on B16F10 mouse melanoma tumors. Systemic expression of the encoded peptides did not induce changes in general demeanor, discomfort or weight changes in mice, implying that intratumor expression would also be non-toxic. We then tested these peptide plasmids therapeutically. Intratumor electroporation delivery of the peptide plasmids to palpable B16F10 mouse melanoma tumors significantly increased tumor doubling time and induced approximately 10% long-term tumor regression. Delivery of a plasmid encoding IL-12 induced long-term tumor regression in approximately 40% of mice as well as a reduction myeloid-derived suppressor cells and T regulatory cells and an increase infiltration of CD8+ T cells, creating an inflamed tumor microenvironment. This modulation of the tumor microenvironment suggested the potentiation of a combination therapy. This combination synergistically increased long-term regression to 80-100%, depending on the peptide plasmid delivered, over either PD-1 peptide or IL-12 gene therapy alone. These results demonstrated that the delivery of immune regulators with differing activities may be a promising and potentially inexpensive alternative to monoclonal antibody therapies. Citation Format: Loree Heller, Guilan Shi, Jody Synowiec, Richard Heller. PD-1 peptide/IL-12 combination gene therapy for the treatment of melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 3289.

Isomerization and decomposition of a Criegee intermediate in the ozonolysis of alkenes: dynamics using a multireference potential.

Polymeric Nanostructure Compiled with Multifunctional Components to Exert Tumor-Targeted Delivery of Antiangiogenic Gene for Tumor Growth Suppression

Effective melanoma immunotherapy with interleukin-2 delivered by a novel polymeric nanoparticle

Polydopamine nanoparticles with different sizes for NIR-promoted gene delivery and synergistic photothermal therapy

Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy.

Dissolving Microneedles Loading TPGS Biphasic Functionalized PLGA Nanoparticles for Efficient Chemo‐Photothermal Combined Therapy of Melanoma

Abstract 3289: PD-1 peptide/IL-12 combination gene therapy for the treatment of melanoma

Low Molecular Weight Heparin-Coated and Dendrimer-Based Core-Shell Nanoplatform with Enhanced Immune Activation and Multiple Anti-Metastatic Effects for Melanoma Treatment

Melanoma Peptide MHC Specific TCR Expressing T-Cell Membrane Camouflaged PLGA Nanoparticles for Treatment of Melanoma Skin Cancer

GSH/pH Dual Response Drug Delivery System for Photothermal Enhanced Gene-Immunotherapy

Targeted Anti-Cancer Therapy: Co-Delivery of VEGF siRNA and Phenethyl isothiocyanate (PEITC) via cRGD-Modified Lipid Nanoparticles for Enhanced Anti-Angiogenic Efficacy

Transdermal Gene Delivery by Functional Peptide-Conjugated Cationic Gold Nanoparticle Reverses the Progression and Metastasis of Cutaneous Melanoma

Nanomaterial‐Mediated Delivery of MLKL Plasmids Sensitizes Tumors to Immunotherapy and Reduces Metastases

Peptide-IR820 Conjugate: A Promising Strategy for Efficient Vascular Disruption and Hypoxia Induction in Melanoma

Photosensitizer-loaded gold nanocages for immunogenic phototherapy of aggressive melanoma

Nanoparticle delivery of anti-metastatic NM23-H1 gene improves chemotherapy in a mouse tumor model

Serum-resistant complex nanoparticles functionalized with imidazole-rich polypeptide for gene delivery to pulmonary metastatic melanoma

Laser Immunotherapy in Combination with Perdurable PD-1 Blocking for the Treatment of Metastatic Tumors

Tumor microenvironment-activated cancer cell membrane-liposome hybrid nanoparticle-mediated synergistic metabolic therapy and chemotherapy for non-small cell lung cancer

SP94-Targeted Triblock Copolymer Nanoparticle Delivers Thymidine Kinase-p53-Nitroreductase Triple Therapeutic Gene and Restores Anticancer Function against Hepatocellular Carcinoma in Vivo

Natural and anthropogenic events influence the soundscapes of four bays on Hawaii Island.